Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GID4 | Q8IVV7 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23274901 | 1.00 | PRCP (0.69) | PRCPGAARECQLGID4OPRM1 | |
| SCHEMBL23274832 | 0.87 | PRCP (0.73) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL29924464 | 0.87 | PRCP (0.73) | PRCPGAARECQLGID4KDM1A | |
| SCHEMBL8222451 | 0.84 | PRCP (0.47) | PRCPGAAMEN1KMT2A | |
| SCHEMBL6084553 | 0.82 | PRCP (1.00) | PRCPGAARECQLGID4OPRM1 | |
| SCHEMBL29560462 | 0.82 | PRCP (1.00) | PRCPGAARECQLGID4OPRM1 | |
| SCHEMBL29561888 | 0.82 | PRCP (1.00) | PRCPGAARECQLGID4OPRM1 | |
| SCHEMBL21095884 | 0.82 | PRCP (1.00) | PRCPGAARECQLGID4OPRM1 | |
| SCHEMBL21063720 | 0.82 | PRCP (1.00) | PRCPGAARECQLGID4OPRM1 | |
| SCHEMBL29560764 | 0.82 | PRCP (1.00) | PRCPGAARECQLGID4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| EP-4048677-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | PRCP 70/4885GAA 178/4885RECQL 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.